OLIPASS CORPORATION
An R&D company developing RNA therapeutics using its proprietary OPNA platform.
244460 | KO
Overview
Corporate Details
- ISIN(s):
- KR7244460002
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 동백중앙로16번길 16-4 에이스동백타워1동 20층, 용인시
Description
OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-09-30 00:00 |
기타경영사항(특허권취득)(자율공시)(SCN9A Antisense Pain Killer)
|
Korean | 5.2 KB | ||
| 2021-09-28 00:00 |
기업설명회(IR)개최
|
Korean | 7.5 KB | ||
| 2021-09-15 00:00 |
기타경영사항(특허권취득)(자율공시)(아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드)
|
Korean | 5.3 KB | ||
| 2021-09-02 00:00 |
기타경영사항(특허권취득)(자율공시)(Exon Skipping by Peptide Nucleic Acid Derivatives)
|
Korean | 4.7 KB | ||
| 2021-08-25 00:00 |
투자판단관련주요경영사항(비마약성진통제(OLP-1002) 호주 임상 2a상 시험 계획 신청)
|
Korean | 10.0 KB | ||
| 2021-08-13 00:00 |
반기보고서 (2021.06)
|
Korean | 1.1 MB | ||
| 2021-07-30 00:00 |
투자판단관련주요경영사항(OLP-1002 비마약성진통제 신약 호주 임상1B상 임상시험 종료)
|
Korean | 14.0 KB | ||
| 2021-07-19 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 169.5 KB | ||
| 2021-07-19 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.9 KB | ||
| 2021-06-22 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 178.0 KB | ||
| 2021-06-17 00:00 |
주식매수선택권부여에관한신고
|
Korean | 15.1 KB | ||
| 2021-06-15 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2021-06-08 00:00 |
[기재정정]기타경영사항(특허권취득)(자율공시)(SCN9A Antisense Pain Killer)
|
Korean | 8.6 KB | ||
| 2021-05-31 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.5 KB | ||
| 2021-05-31 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 172.0 KB |
Automate Your Workflow. Get a real-time feed of all OLIPASS CORPORATION filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OLIPASS CORPORATION
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OLIPASS CORPORATION via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
